Cell Therapy as Target Therapy against Colon Cancer Stem Cells
Open accessThe DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Abstract
Cancer stem cells (CSCs) are a small subpopulation of cells within tumors with properties, such as self-renewal, differentiation, and tumorigenicity. CSCs have been proposed as a plausible therapeutic target as they are responsible for tumor recurrence, metastasis, and conventional therapy resistance. Selectively targeting CSCs is a promising strategy to eliminate the propagation of tumor cells and impair overall tumor development. Recent research shows that several immune cells play a crucial role in regulating tumor cell proliferation by regulating different CSC maintenance or proliferation pathways. There have been great advances in cellular immunotherapy using T cells, natural killer (NK) cells, macrophages, or stem cells for the selective targeting of tumor cells or CSCs in colorectal cancer (CRC). This review summarizes the CRC molecular profiles that may benefit from said therapy and the main vehicles used in cell therapy against CSCs. We also discuss the challenges, limitations, and advantages of combining conventional and/or current targeted treatments in the late stages of CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806 · cited 2×
“The HIF-1/CXCR4 pathway can be targeted to prevent TAM buildup [86,87].”
BackgroundCombination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008) · Nature Genetics · doi:10.1038/ng.127 · Cited by 2,523
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940 · cited 1×
“Several cytokines suppress tumor growth by the selective induction of apoptosis or by potentially infiltrating adaptive and innate immune cells [98].”
BackgroundTargeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
Chanmee, T., Ontong, P., Konno, K., & Itano, N. (2014) · Cancers · doi:10.3390/cancers6031670 · Cited by 1,538
Cytokines in clinical cancer immunotherapy
Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberria, I., Aznar, M. A., Pérez-Gracia, J. L., Rodríguez-Ruiz, M. E., Ponz-Sarvise, M., Castañón, E., & Melero, I. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,205
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
Clinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044 · cited 1×
“T cells hardly exert several cell functions associated with hypofunction, cell exhaustion, and reduced efficacy, possibly resulting in treatment failure [132].”
BackgroundParkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment
Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y. (2018) · Stem Cells International · doi:10.1155/2018/5416923 · Cited by 994
Hossain, M. S., Karuniawati, H., Jairoun, A. A., Urbi, Z., Ooi, D. J., John, A., Lim, Y. C., Kibria, K. M. K., Mohiuddin, A. K. M., Ming, L. C., et al. (2022) · Cancers · doi:10.3390/cancers14071732 · Cited by 920 · cited 1×
“Available treatment is crucial for advanced CRC to improve prognosis, and it must correlate with the cost of current therapies [138].”
BackgroundZacharakis, N., Chinnasamy, H., Black, M., Xu, H., Lu, Y.-C., Zheng, Z., Pasetto, A., Langhan, M., Shelton, T., Prickett, T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0040-8 · Cited by 773
NK cell-based cancer immunotherapy: from basic biology to clinical development
Liu, S., Galat, V., Galat4, Y., Lee, Y. K. A., Wainwright, D., & Wu, J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01014-w · Cited by 689
Stevanović, S., Draper, L. M., Langhan, M. M., Campbell, T. E., Kwong, M. L., Wunderlich, J. R., Dudley, M. E., Yang, J. C., Sherry, R. M., Kammula, U. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9093 · Cited by 682
Combination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654 · cited 1×
“Strategies that combine IFN with tumor-specific antibodies or standard chemotherapeutic medications, effectively inhibit cancer progression in animal models [97].”
BackgroundGeorgoudaki, A.-M., Prokopec, K. E., Boura, V. F., Hellqvist, E., Sohn, S., Östling, J., Dahan, R., Harris, R. A., Rantalainen, M., Klevebring, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.084 · Cited by 609 · cited 12×
“For instance, Georgoudaki et al. evaluated the impact of immune checkpoint therapy by repolarizing TAMs to the M1 type and inducing anticancer activity in a mouse model of MC38 colon cancer by suppressing the expression of the macrophage receptor with collagenous structure (MARCO) by TAMs [84,88].”
MethodInfluentialChmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 562
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
Sivori, S., Vacca, P., Del Zotto, G., Munari, E., Mingari, M. C., & Moretta, L. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0206-4 · Cited by 555
Halama, N., Zoernig, I., Berthel, A., Kahlert, C., Klupp, F., Suarez-Carmona, M., Suetterlin, T., Brand, K., Krauss, J., Lasitschka, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.005 · Cited by 495
Engineering and Design of Chimeric Antigen Receptors
Guedan, S., Calderon, H., Posey, A. D., & Maus, M. V. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.009 · Cited by 453
Colon Cancer Stem Cells: Promise of Targeted Therapy
Todaro, M., Francipane, M. G., Medema, J. P., & Stassi, G. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.063 · Cited by 443
Adipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy
Kucerova, L., Altanerova, V., Matuskova, M., Tyciakova, S., & Altaner, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4024 · Cited by 431 · cited 1×
“Adipose tissue-derived, MSC engineered to express yeast CD inhibited colon cancer growth when combined with 5-FU in an immunocompromised mouse model [113].”
BackgroundCAR-T cells: the long and winding road to solid tumors
D’Aloia, M. M., Zizzari, I. G., Sacchetti, B., Pierelli, L., & Alimandi, M. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0278-6 · Cited by 399
Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment
Aponte, P. M., & Caicedo, A. (2017) · Stem Cells International · doi:10.1155/2017/5619472 · Cited by 375
Wang, H., Tian, T., & Zhang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168470 · Cited by 364
Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?
Gires, O., Pan, M., Schinke, H., Canis, M., & Baeuerle, P. A. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09898-3 · Cited by 351
Tumor infiltrating lymphocytes in ovarian cancer
Santoiemma, P. P., & Powell, D. J. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1040960 · Cited by 337
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1211 · Cited by 302
Differentiation of human NK cells into NK1 and NK2 subsets.
Peritt, D., Robertson, S., Gri, G., et al. (1998) · PubMed · Cited by 268
Dafni, U., Michielin, O., Lluesma, S. M., Tsourti, Z., Polydoropoulou, V, Karlis, D., Besser, M. J., Haanen, J., Svane, I. M., Ohashi, P. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz398 · Cited by 263
Cutting Edge: Differentiation of Human NK Cells into NK1 and NK2 Subsets
Peritt, D., Robertson, S., Gri, G., Showe, L., Aste-Amezaga, M., & Trinchieri, G. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.11.5821 · Cited by 237
CD133: beyond a cancer stem cell biomarker
Barzegar Behrooz, A., Syahir, A., & Ahmad, S. (2019) · Journal of Drug Targeting · doi:10.1080/1061186x.2018.1479756 · Cited by 235
Vaiopoulos, A. G., Kostakis, I. D., Koutsilieris, M., & Papavassiliou, A. G. (2012) · STEM CELLS · doi:10.1002/stem.1031 · Cited by 231
Cancer stem cells: A brief review of the current status
Kuşoğlu, A., & Biray Avcı, Ç. (2019) · Gene · doi:10.1016/j.gene.2018.09.052 · Cited by 221
Immunotherapy of cancer by IL-12-based cytokine combinations
Weiss, J. M., Subleski, J. J., Wigginton, J. M., & Wiltrout, R. H. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.11.1705 · Cited by 221
Principles of adoptive T cell therapy in cancer
Met, Ö., Jensen, K. M., Chamberlain, C. A., Donia, M., & Svane, I. M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-018-0703-z · Cited by 213
Stintzing, S., Wirapati, P., Lenz, H.-J., Neureiter, D., Fischer von Weikersthal, L., Decker, T., Kiani, A., Kaiser, F., Al-Batran, S., Heintges, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz387 · Cited by 197
CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment
Jin, J., Lin, J., Xu, A., Lou, J., Qian, C., Li, X., Wang, Y., Yu, W., & Tao, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722916 · Cited by 190
Natural killer cells: a promising immunotherapy for cancer
Chu, J., Gao, F., Yan, M., Zhao, S., Yan, Z., Shi, B., & Liu, Y. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03437-0 · Cited by 181
Zhang, X., Powell, K. A., & Li, L. (2020) · Cancers · doi:10.3390/cancers12123765 · Cited by 176
Seo, A. N., Kwak, Y., Kim, D.-W., Kang, S.-B., Choe, G., Kim, W. H., & Lee, H. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098528 · Cited by 175
Targeted Delivery Methods for Anticancer Drugs
Veselov, V. V., Nosyrev, A. E., Jicsinszky, L., Alyautdin, R. N., & Cravotto, G. (2022) · Cancers · doi:10.3390/cancers14030622 · Cited by 174
Expression of TRAIL and TRAIL receptors in normal and malignant tissues
DANIELS, R. A., TURLEY, H., KIMBERLEY, F. C., LIU, X. S., MONGKOLSAPAYA, J., CH'EN, P., XU, X. N., JIN, B., PEZZELLA, F., & SCREATON, G. R. (2005) · Cell Research · doi:10.1038/sj.cr.7290311 · Cited by 173
The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials
Snajdauf, M., Havlova, K., Vachtenheim, J., Ozaniak, A., Lischke, R., Bartunkova, J., Smrz, D., & Strizova, Z. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.628332 · Cited by 169
Nieda, M., Nicol, A., Koezuka, Y., Kikuchi, A., Lapteva, N., Tanaka, Y., Tokunaga, K., Suzuki, K., Kayagaki, N., Yagita, H., et al. (2001) · Blood · doi:10.1182/blood.v97.7.2067 · Cited by 166
Biological and Genetic Characteristics of Tumor-Initiating Cells in Colon Cancer
Ieta, K., Tanaka, F., Haraguchi, N., Kita, Y., Sakashita, H., Mimori, K., Matsumoto, T., Inoue, H., Kuwano, H., & Mori, M. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9605-3 · Cited by 161
Afrăsânie, V.-A., Marinca, M. V., Alexa-Stratulat, T., Gafton, B., Păduraru, M., Adavidoaiei, A. M., Miron, L., & Rusu, C. (2019) · Radiology and Oncology · doi:10.2478/raon-2019-0033 · Cited by 159
Zhang, Q., Zhang, H., Ding, J., Liu, H., Li, H., Li, H., Lu, M., Miao, Y., Li, L., & Zheng, J. (2018) · Journal of Immunology Research · doi:10.1155/2018/4263520 · Cited by 156
NK cells and T cells cooperate during the clinical course of colorectal cancer
Sconocchia, G., Eppenberger, S., Spagnoli, G. C., Tornillo, L., Droeser, R., Caratelli, S., Ferrelli, F., Coppola, A., Arriga, R., Lauro, D., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.952197 · Cited by 155
Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis
Hou, B., Tang, Y., Li, W., Zeng, Q., & Chang, D. (2019) · Disease Markers · doi:10.1155/2019/3425291 · Cited by 152
A review on development of MUC1-based cancer vaccine
Gao, T., Cen, Q., & Lei, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110888 · Cited by 151
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
von Locquenghien, M., Rozalén, C., & Celià-Terrassa, T. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143296 · Cited by 149
Singh, M. P., Rai, S., Pandey, A., Singh, N. K., & Srivastava, S. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2019.10.013 · Cited by 146
Magee, M. S., Abraham, T. S., Baybutt, T. R., Flickinger, J. C., Ridge, N. A., Marszalowicz, G. P., Prajapati, P., Hersperger, A. R., Waldman, S. A., & Snook, A. E. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0362 · Cited by 143 · cited 1×
“In a syngeneic murine model of CRC, GUCY2C CAR-T cells provided long-term protection against lung metastases [62].”
BackgroundYip, J. L. K., Balasuriya, G. K., Spencer, S. J., & Hill‐Yardin, E. L. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.08.021 · Cited by 143
Effect of Natural Compounds on NK Cell Activation
Grudzień, M., & Rapak, A. (2018) · Journal of Immunology Research · doi:10.1155/2018/4868417 · Cited by 139
miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
Huang, Q., Xia, J., Wang, L., Wang, X., Ma, X., Deng, Q., Lu, Y., Kumar, M., Zhou, Z., Li, L., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0600-x · Cited by 135
Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133
Retroviral vector‐producing mesenchymal stem cells for targeted suicide cancer gene therapy
Uchibori, R., Okada, T., Ito, T., Urabe, M., Mizukami, H., Kume, A., & Ozawa, K. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1313 · Cited by 128
Parkhurst, M. R., Joo, J., Riley, J. P., Yu, Z., Li, Y., Robbins, P. F., & Rosenberg, S. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1638 · Cited by 122
Schmohl, J. U., Gleason, M. K., Dougherty, P. R., Miller, J. S., & Vallera, D. A. (2016) · Targeted Oncology · doi:10.1007/s11523-015-0391-8 · Cited by 112
Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update
Eyvazi, S., Farajnia, S., Dastmalchi, S., Kanipour, F., Zarredar, H., & Bandehpour, M. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009618666180102102311 · Cited by 107
T-cell-based immunotherapy in colorectal cancer
Feng, M., Zhao, Z., Yang, M., Ji, J., & Zhu, D. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.040 · Cited by 107
Kikuchi, Y., Kunita, A., Iwata, C., Komura, D., Nishiyama, T., Shimazu, K., Takeshita, K., Shibahara, J., Kii, I., Morishita, Y., et al. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.11.012 · Cited by 107
Therapeutic Strategies Targeting Cancer Stem Cells and Their Microenvironment
Sun, H.-R., Wang, S., Yan, S.-C., Zhang, Y., Nelson, P. J., Jia, H.-L., Qin, L.-X., & Dong, Q.-Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01104 · Cited by 103
Rettinger, E., Kuçi, S., Naumann, I., Becker, P. S. A., Kreyenberg, H., Anzaghe, M., Willasch, A. M., Koehl, U., Bug, G., Ruthardt, M., et al. (2011) · Cytotherapy · doi:10.3109/14653249.2011.613931 · Cited by 101
Mueller, L. P., Luetzkendorf, J., Widder, M., Nerger, K., Caysa, H., & Mueller, T. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.68 · Cited by 98
Pernot, S., Évrard, S., & Khatib, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850856 · Cited by 98
Hombach, A. A., Geumann, U., Günther, C., Hermann, F. G., & Abken, H. (2020) · Cells · doi:10.3390/cells9040873 · Cited by 96
Frank, M. H., Wilson, B. J., Gold, J. S., & Frank, N. Y. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.080 · Cited by 95
Hypoxia Selectively Impairs CAR-T Cells In Vitro
Berahovich, R., Liu, X., Zhou, H., Tsadik, E., Xu, S., Golubovskaya, V., & Wu, L. (2019) · Cancers · doi:10.3390/cancers11050602 · Cited by 94
Liang, K.-H., Tso, H.-C., Hung, S.-H., Kuan, I., Lai, J.-K., Ke, F.-Y., Chuang, Y., Liu, I.-J., Wang, Y., Chen, R., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.040 · Cited by 94
von Einem, J. C., Guenther, C., Volk, H., Grütz, G., Hirsch, D., Salat, C., Stoetzer, O., Nelson, P. J., Michl, M., Modest, D. P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32230 · Cited by 93
El-Deiry, W. S., Vijayvergia, N., Xiu, J., Scicchitano, A., Lim, B., Yee, N. S., Harvey, H. A., Gatalica, Z., & Reddy, S. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1113356 · Cited by 91
The Cytokine Network in Colorectal Cancer: Implications for New Treatment Strategies
Braumüller, H., Mauerer, B., Andris, J., Berlin, C., Wieder, T., & Kesselring, R. (2022) · Cells · doi:10.3390/cells12010138 · Cited by 90
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
Aparicio, C., Belver, M., Enríquez, L., Espeso, F., Núñez, L., Sánchez, A., de la Fuente, M. Á., & González-Vallinas, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111781 · Cited by 86
Zhang, T., Huang, B. Y., Wu, H., Wu, J., Li, L., Li, Y.-X., Hu, Y., Han, M. Y., Shen, Y., Tabata, Y., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.007 · Cited by 86
EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis
Feng, Y., Dai, X., Li, X., Wang, H., Liu, J., Zhang, J., Du, Y., & Xia, L. (2012) · Cell Proliferation · doi:10.1111/j.1365-2184.2012.00837.x · Cited by 83
Olsson, A., Nakhlé, J., Sundstedt, A., Plas, P., Bauchet, A.-L., Pierron, V., Bruetschy, L., Deronic, A., Törngren, M., Liberg, D., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0098-5 · Cited by 78
Targeting stemness of cancer stem cells to fight colorectal cancers
Du, L., Cheng, Q., Zheng, H., Liu, J., Liu, L., & Chen, Q. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.012 · Cited by 76
HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer
Xu, J., Meng, Q., Sun, H. X., Zhang, X., Yun, J., Li, B., Wu, S., Li, X., Yang, H., Zhu, H., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04100-0 · Cited by 76
Korehisa, S., Oki, E., Iimori, M., Nakaji, Y., Shimokawa, M., Saeki, H., Okano, S., Oda, Y., & Maehara, Y. (2018) · International Journal of Cancer · doi:10.1002/ijc.31107 · Cited by 75
Zhi, Y., Mou, Z., Chen, J., He, Y., Dong, H. F., Fu, X., & Wu, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135528 · Cited by 74
Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression
Jones, A. B., Rocco, A., Lamb, L. S., Friedman, G. K., & Hjelmeland, A. B. (2022) · Cancers · doi:10.3390/cancers14092339 · Cited by 72
O'Malley, G., Heijltjes, M., Houston, A. M., Rani, S., Ritter, T., Egan, L. J., & Ryan, A. E. (2016) · Oncotarget · doi:10.18632/oncotarget.11354 · Cited by 71
Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
Sur, D. G., Havasi, A. D., Cainap, C. I., Samaşcă, G., Burz, C. C., Bălăcescu, O., Lupan, I., Deleanu, D. M., & Irimie, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010182 · Cited by 70
Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature
Aravindhan, S., Ejam, S. S., Lafta, M. H., Markov, A., Yumashev, A. V., & Ahmadi, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01836-9 · Cited by 70
Portillo, A. L., Hogg, R., Poznanski, S. M., Rojas, E. A. P., Cashell, N. J., Hammill, J. A., Chew, M. V., Shenouda, M. M., Ritchie, T. M., Cao, Q., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102619 · Cited by 69
MUC1-C drives stemness in progression of colitis to colorectal cancer
Li, W., Zhang, N., Jin, C., Long, M. D., Rajabi, H. N., Yasumizu, Y., Fushimi, A., Yamashita, N., Hagiwara, M., Zheng, R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.137112 · Cited by 66
Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach
Valenzuela, G., Canepa, J., Simonetti, C., de Zaldívar, L. S., Marcelain, K., & González‐Montero, J. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i11.1000 · Cited by 63
De Angelis, M. L., Zeuner, A., Policicchio, E., Russo, G., Bruselles, A., Signore, M., Vitale, S., De Luca, G., Pilozzi, E., Boe, A., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0214 · Cited by 60
Bai, J., Chen, H., & Bai, X. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23810 · Cited by 59
CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety
Li, H., Yang, C., Cheng, H., Huang, S., & Zheng, Y. (2021) · Journal of Cancer · doi:10.7150/jca.50509 · Cited by 58
Rossignoli, F., Spano, C., Grisendi, G., Foppiani, E. M., Golinelli, G., Mastrolia, I., Bestagno, M., Candini, O., Petrachi, T., Recchia, A., et al. (2019) · Theranostics · doi:10.7150/thno.27576 · Cited by 55
CD133: An emerging prognostic factor and therapeutic target in colorectal cancer
Akbari, M., Shomali, N., Faraji, A., Shanehbandi, D., Asadi, M., Mokhtarzadeh, A., Shabani, A., & Baradaran, B. (2020) · Cell Biology International · doi:10.1002/cbin.11243 · Cited by 49
Guo, Y., Zhang, Z., Xu, X., Xu, Z., Wang, S., Huang, D., Li, Y., Mou, X., Liu, F., & Xiang, C. (2019) · Stem Cells and Development · doi:10.1089/scd.2018.0222 · Cited by 49
Dendritic cell-based cancer immunotherapy for colorectal cancer
Kajihara, M., Takakura, K., Kanai, T., Ito, Z., Saito, K., Takami, S., Shimodaira, S., Okamoto, M., Ohkusa, T., & Koido, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i17.4275 · Cited by 49
Dendritic cell vaccine therapy for colorectal cancer
Wooster, A. L., Girgis, L. H., Brazeale, H., Anderson, T. S., Wood, L. M., & Lowe, D. B. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105374 · Cited by 48
Fusco, N., & Bòsari, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i35.7926 · Cited by 48
Alieva, M., Bagó, J. R., Aguilar, E., Soler‐Botija, C., Vila, O. F., Molet, J., Gambhir, S. S., Rubio, N., & Blanco, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035148 · Cited by 47
NK Cell-Based Immunotherapy in Colorectal Cancer
Chiesa, M. D., Setti, C., Giordano, C., Obino, V., Greppi, M., Pesce, S., Marcenaro, E., Rutigliani, M., Provinciali, N., Paleari, L., et al. (2022) · Vaccines · doi:10.3390/vaccines10071033 · Cited by 47
CAR T-cells for colorectal cancer immunotherapy: Ready to go?
Ghazi, B., El Ghanmi, A., Kandoussi, S., Ghouzlani, A., & Badou, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978195 · Cited by 46
Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation
Ruggeri, L., Mancusi, A., Burchielli, E., Aversa, F., Martelli, M. P., & Velardi, A. (2006) · Cytotherapy · doi:10.1080/14653240601078721 · Cited by 44
Feng, H., Zhao, J., Schiergens, T. S., Wang, P., Ou, B., Al-Sayegh, R., Li, M.-L., Lu, A., Yin, S., & Thasler, W. E. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.415 · Cited by 41
Ivanova, M. D., Venetis, K., Guerini‐Rocco, E., Bottiglieri, L., Mastropasqua, M. G., Garrone, O., Fusco, N., & Ghidini, M. (2022) · Life · doi:10.3390/life12091403 · Cited by 40
Personalized medicine: Stem cells in colorectal cancer treatment
Patsalias, A., & Kozovská, Z. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111821 · Cited by 39
Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts
Zhu, Cheng, M., Yang, Z., Zeng, C., Chen, J., Xie, Y., Luo, S., Zhang, K., Zhou, S.-F., & Lv, N. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s71466 · Cited by 38 · cited 1×
“The systemic administration of MSC transduced with inhibitor NK4 suppressed the growth of gastric cancer xenografts and reduced intra-tumoral vascularization [96,115].”
BackgroundAbbasian, M., Mousavi, E., Arab‐Bafrani, Z., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27619 · Cited by 38
Chan, L. Y., Dass, S. A., Tye, G. J., Imran, S. A. M., Zaman, W. S. W. K., & Nordin, F. (2022) · Biomedicines · doi:10.3390/biomedicines10040804 · Cited by 38
Arming Mesenchymal Stromal/Stem Cells Against Cancer: Has the Time Come?
Golinelli, G., Mastrolia, I., Aramini, B., Masciale, V., Pinelli, M., Pacchioni, L., Casari, G., Dall’Ora, M., Soares, M. B. P., Damasceno, P. K. F., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.529921 · Cited by 37
Lin, C., Liao, T., & Yang, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.588542 · Cited by 35
MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine
Guo, M., Luo, B., Pan, M., Li, M., Zhao, F., & Dou, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106631 · Cited by 34
Ma, X., Liu, J., Yang, X., Fang, K., Zheng, P., Liang, X., & Liu, J. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220910690 · Cited by 32
HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
Styczen, H., Nagelmeier, I., Beissbarth, T., Nietert, M., Homayounfar, K., Sprenger, T., Boczek, U., Stanek, K., Kitz, J., Wolff, H. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3527 · Cited by 29
Fu, Y., Ni, J., Chen, J., Ma, G., Zhao, M., Zhu, S., Shi, T., Zhu, J., Huang, Z., Zhang, J., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.020 · Cited by 29
HER2 Regulates Cancer Stem Cell Activities via the Wnt Signaling Pathway in Gastric Cancer Cells
Jung, D. H., Bae, Y. J., Kim, J., Shin, Y. K., & Jeung, H. (2019) · Oncology · doi:10.1159/000502845 · Cited by 28
Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review
Juat, D. J., Hachey, S. J., Billimek, J., Rosario, M. P. D., Nelson, E. L., Hughes, C. C. W., & Zell, J. A. (2022) · The Oncologist · doi:10.1093/oncolo/oyab038 · Cited by 27
The Effects of Mesenchymal Stem Cell on Colorectal Cancer
Yuan, J., Wei, Z., Xu, X., Ocansey, D. K. W., Cai, X. J., & Mao, F. (2021) · Stem Cells International · doi:10.1155/2021/9136583 · Cited by 25
Guo, M., Luo, B., Pan, M., Li, M., Xu, H., Zhao, F., & Dou, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106850 · Cited by 25
Anti-tumor effects of engineered mesenchymal stem cells in colon cancer model
Yang, J., Lv, K., Sun, J., & Guan, J. (2019) · Cancer Management and Research · doi:10.2147/cmar.s209880 · Cited by 23
Vito, A. D., Orecchia, P., Balza, E., Reverberi, D., Scaldaferri, D., Taramelli, R., Noonan, D. M., Acquati, F., & Mortara, L. (2020) · Cancers · doi:10.3390/cancers12030717 · Cited by 23
Behind the Adaptive and Resistance Mechanisms of Cancer Stem Cells to TRAIL
Quiroz-Reyes, A. G., González, P. D., Islas, J. F., Delgado-Gallegos, J. L., Martínez‐Garza, J. H., & Garza-Treviño, E. N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071062 · Cited by 23
Self-citationHo, C.-T., Wu, M.-H., Chen, M., Lin, S., Yen, Y., & Hung, S. (2021) · Biomedicines · doi:10.3390/biomedicines9050548 · Cited by 22
HSV-TK Expressing Mesenchymal Stem Cells Exert Inhibitory Effect on Cervical Cancer Model.
Kenarkoohi, A., Bamdad, T., Soleimani, M., et al. (2020) · PubMed · doi:10.22088/ijmcm.bums.9.2.146 · Cited by 20
γδ T Cells as a Potential Tool in Colon Cancer Immunotherapy
Ramutton, T., Buccheri, S., Dieli, F., Todaro, M., Stassi, G., & Meraviglia, S. (2014) · Immunotherapy · doi:10.2217/imt.14.59 · Cited by 20
NK cell upraise in the dark world of cancer stem cells
Shokouhifar, A., Firouzi, J., Nouri, M., Sarab, G. A., & Ebrahimi, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02400-1 · Cited by 18
Guo, M., You, C., Dong, W., Luo, B., Wu, Y.-H., Chen, Y., Li, J., Pan, M., Li, M., Zhao, F., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110804 · Cited by 16
Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer.
Yoshida, Y., Naito, M., Yamada, T., Aisu, N., Kojima, D., Mera, T., Tanaka, T., Naito, K., Yasumoto, K., Kamigaki, T., et al. (2016) · PubMed · Cited by 16
Stem Cells as Therapeutic Targets in Colorectal Cancer
Zalewski, A., Snook, A. E., & Waldman, S. A. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0099 · Cited by 15
Advances in adoptive cellular therapy for colorectal cancer: A narrative review
Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14 · cited 1×
“Procuring infusion of a higher T cell ratio can extend the effective cells; however, it may be inconvenient for advanced CRC as it may demand more time to manufacture [133].”
BackgroundYe, F., Gao, S., Gao, Y., Wang, X., & Chen, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.13233 · Cited by 14
Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer
Włodarczyk, M., Włodarczyk, J., Siwiński, P., Sobolewska-Włodarczyk, A., & Fichna, J. (2018) · Current Drug Targets · doi:10.2174/1389450119666180803122744 · Cited by 14
Wang, Y., Zheng, X., Wei, H., et al. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2008.02.011 · Cited by 11
Aspectos inmunológicos de la leucemia mieloblástica aguda
González, B., Bueno, D., Rubio, P., Román, S. S., Plaza, D., Sastre, A., García-Miguel, P., Fernández, L., Valentín, J., Martinez, I. S., et al. (2015) · Anales de Pediatría · doi:10.1016/j.anpedi.2015.07.004 · Cited by 6
A Novel Molecular Analysis Approach in Colorectal Cancer Suggests New Treatment Opportunities
López‐Camacho, E., Prado-Vázquez, G., Martínez-Pérez, D., Ferrer-Gómez, M., Llorente-Armijo, S., López‐Vacas, R., Díaz‐Almirón, M., Gámez‐Pozo, A., Vara, J. Á. F., Feliú, J., et al. (2023) · Cancers · doi:10.3390/cancers15041104 · Cited by 6
Carrell, R. K., Stanton, R. A., Ethier, S. P., LaRue, A. C., & Soloff, A. C. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.09.010 · Cited by 5
An immunological approach to acute myeloid leukaemia
González, B., Bueno, D., Rubio, P., Román, S. S., Plaza, D., Sastre, A., García-Miguel, P., Fernández, L., Valentín, J., Martinez, I. S., et al. (2016) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2015.07.028 · Cited by 5
A novel molecular analysis approach in colorectal cancer suggests new treatment opportunities
López-Camacho, E., Prado-Vázquez, G., Martínez-Pérez, D., Ferrer-Gómez, M., Llorente-Armijo, S., Vacas, R. L., Almirón, M. D., Gámez-Pozo, A., Vara, J. Á. F., Feliu, J., et al. (2023) · doi:10.1101/2023.01.13.23284526
Research works printed but not linked: 1
- Abbas A.K. Lichtman A.H. Pober J.S. Cellular and Molecular Immunology W.B. Saunders Company Philadelphia, PA, USA 1997
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Furthermore, T cells can be engineered to express CARs that selectively target CSC markers, leading to improved recognition and destruction of CSCs, which are commonly resistant to T cell therapy [180].”
Influential
Metadata
- Authors
- Garza Treviño, E. N., Quiroz Reyes, A. G., Rojas Murillo, J. A., de la Garza Kalife, D. A., Delgado Gonzalez, P., Islas, J. F., Estrada Rodriguez, A. E., & Gonzalez Villarreal, C. A.
- Affiliations
- Laboratorio de Terapia Celular, Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Av. Dr. José Eleuterio González 235, Monterrey 64460, Nuevo León, Mexico
- Departamento de Ciencias Básicas, Vicerrectoría de Ciencias de la Salud, Universidad de Monterrey, Ignacio Morones Prieto 4500. Jesus M. Garza, San Pedro Garza García 66238, Nuevo León, Mexico
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-05-03
- Volume
- 24
- Issue
- 9
- Pages
- 8163
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10179203
- OpenAlex
- W4368367175
- Cited by
- 24
- References
- 141
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 7
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- colorectal cancer, cancer stem cells, cell therapy, cellular immunotherapy, tumor recurrence, metastasis, treatment resistance, T cells, natural killer cells, macrophages, stem cell therapy, tumor microenvironment, combination therapy
- MeSH terms
- Colonic Neoplasms, Humans, Immunotherapy, Neoplasm Recurrence, Local, Neoplastic Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.